Evidence map›Paper›PMID 41673170›Full record

ArticleNature cell biology2026

Tumour acidosis remodels the glycocalyx to control lipid scavenging and ferroptosis.

Anna Bång-Rudenstam, Myriam Cerezo-Magaña, Marton Horvath, Hugo Talbot, Emma Gustafsson, Stevanus Jonathan, Chaitali Chakraborty, Itzel Nissen, Kelin Gonçalves de Oliveira, Axel Boukredine and 13 more

Abstract read
In one paragraph

Article in Nature cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Anna Bång-RudenstamDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-2706-9502
Myriam Cerezo-MagañaDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-9752-8917
Marton HorvathDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-5297-7735
Hugo TalbotDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-9774-8573
Emma GustafssonDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.ORCID http://orcid.org/0009-0007-7005-912X
Stevanus JonathanDepartment of Clinical Sciences, Division of Neurosurgery, Lund University, Lund, Sweden.ORCID http://orcid.org/0009-0000-4349-5371
Chaitali ChakrabortyDepartment of Medical and Translational Biology, Section of Molecular Medicine, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0003-3927-0799
Itzel NissenDepartment of Medical and Translational Biology, Section of Molecular Medicine, Umeå University, Umeå, Sweden.
Kelin Gonçalves de OliveiraDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-1646-5657
Axel BoukredineDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.ORCID http://orcid.org/0009-0006-3714-6769
Sarah BeyerDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.
Julio Enriquez PerezDepartment of Clinical Sciences, Division of Neurosurgery, Lund University, Lund, Sweden.
Maria C JohanssonDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0003-0075-3187
Lena KjellénDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0003-3973-918X
Emil TykessonDepartment of Experimental Medical Science, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-0511-9831
Anders MalmströmDepartment of Experimental Medical Science, Lund University, Lund, Sweden.
Toin H van KuppeveltDepartment of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
Karin Forsberg-NilssonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID http://orcid.org/0000-0003-0692-6245
Jeffrey D EskoGlycobiology Research and Training Center, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-8322-1834
Silvia RemeseiroDepartment of Medical and Translational Biology, Section of Molecular Medicine, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0001-5343-007X
Johan BengzonDepartment of Clinical Sciences, Division of Neurosurgery, Lund University, Lund, Sweden.
Valeria GovernaDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-9999-0590
Mattias BeltingDepartment of Clinical Sciences, Division of Oncology, Lund University, Lund, Sweden. mattias.belting@med.lu.se.ORCID http://orcid.org/0000-0003-1585-5434

Funding

Protein Glycosylation in the Coagulopathy and Inflammation of SepsisP01HL131474 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI MAHAN, MICHAEL J · 2016 to 2025
$26.2M
Barncancerfonden (Swedish Childhood Cancer Foundation) PR2022-0117Barncancerfonden (Swedish Childhood Cancer Foundation) PR2023-0078Cancerfonden (Swedish Cancer Society) 23 2655 PJCancerfonden (Swedish Cancer Society) 23 2937 PjCancerfonden (Swedish Cancer Society) 24 366 PjNHLBI NIH HHS P01 HL131474U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL131474Vetenskapsrådet (Swedish Research Council) 2023-02106Vetenskapsrådet (Swedish Research Council) 2024-02736
6 · The paper itself

Abstract

Aggressive tumours are defined by microenvironmental stress adaptation and metabolic reprogramming. Within this niche, lipid droplet accumulation has emerged as a key strategy to buffer toxic lipids and suppress ferroptosis. Lipid droplet formation can occur via de novo lipogenesis or extracellular lipid-scavenging. However, how tumour cells coordinate these processes remains poorly understood. Here we identify a chondroitin sulfate (CS)-enriched glycocalyx as a hallmark of the acidic microenvironment in glioblastoma and central nervous system metastases. This CS-rich glycocalyx encapsulates tumour cells, limits lipid particle uptake and protects against lipid-induced ferroptosis. Mechanistically, we demonstrate that converging hypoxia-inducible factor and transforming growth factor beta signalling induces a glycan switch on syndecan-1-replacing heparan sulfate with CS-thereby impairing its lipid-scavenging function. Dual inhibition of CS biosynthesis and diacylglycerol O-acyltransferase-1, a critical enzyme in lipid droplet formation, triggers catastrophic lipid peroxidation and ferroptotic cell death. These findings define glycan remodelling as a core determinant of metabolic plasticity, positioning the dynamic glycocalyx as a master regulator of nutrient access, ferroptotic sensitivity and therapeutic vulnerability in cancer.

Indexed as

AcidosisFerroptosisGlioblastomaGlycocalyxLipid MetabolismAnimalsCell Line, TumorChondroitin SulfatesHumansLipid PeroxidationMetabolic ReprogrammingMiceSignal TransductionTransforming Growth Factor betaTumor MicroenvironmentChondroitin SulfatesTransforming Growth Factor beta

Identifiers

PMID41673170
PMCPMC12992114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.